SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1119)11/10/2000 10:46:00 PM
From: Ian@SI  Read Replies (1) of 1321
 
Yes, this sounds like very good news.

ATLANTA -- The U.S. Health Care Financing Administration has issued
its national coverage policy for Visudyne therapy in patients with
predominantly classic choroidal neovascularization secondary to
age-related macular degeneration.

In a news release, QLT Inc. (QLTI) and CIBA Vision Corp. said the
decision is the result of a series of consultations with physicians, clinical
investigators and representatives from both CIBA and QLT.

The companies said HCFA's policy clarifies that the level of visual acuity at
which patients may be eligible for Visudyne therapy will be left to the
judgement of the treating physician.

"This decision now clarifies the reimbursement status of Visudyne," the
companies said.

Visudyne is approved for commercial use to treat age-related macular
degeneration, a leading cause of blindness.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News